“Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S62, https://doi.org/10.25251/skin.2.62.